Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$8.37
$8.37
$2.66
$8.55
$401.26M0.522.97 million shsN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$2.60
+4.4%
$2.20
$0.40
$3.10
$200.75M2.052.21 million shs3.71 million shs
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$17.06
$17.06
$2.13
$18.00
$834.46MN/A11,851 shs39 shs
Evolus, Inc. stock logo
EOLS
Evolus
$9.73
+0.7%
$9.81
$8.67
$17.82
$622.83M0.97761,589 shs555,550 shs
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$1.03
$1.01
$0.32
$1.57
$211.41M2.151.93 million shsN/A
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
+3.75%+0.40%-5.32%+403.44%+84.44%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00%0.00%0.00%0.00%0.00%
Evolus, Inc. stock logo
EOLS
Evolus
+4.32%+4.89%+0.10%+2.66%-13.52%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
4.2022 of 5 stars
3.51.00.04.72.11.71.3
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.9225 of 5 stars
3.50.00.03.52.33.30.6
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.5506 of 5 stars
0.00.00.04.70.60.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
0.00
N/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3.00
Buy$5.33105.13% Upside
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
0.00
N/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
3.00
Buy$23.75144.09% Upside
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EOLS, CTMX, CNCE, SPPI, and CXRXF Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$2.50 ➝ $5.00
5/15/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeNeutral ➝ Buy$5.00 ➝ $5.00
5/12/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$5.00 ➝ $6.00
5/8/2025
Evolus, Inc. stock logo
EOLS
Evolus
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$22.00 ➝ $22.00
4/17/2025
Evolus, Inc. stock logo
EOLS
Evolus
BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$21.00
4/14/2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight ➝ Overweight$3.25 ➝ $2.50
4/10/2025
Evolus, Inc. stock logo
EOLS
Evolus
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$27.00 ➝ $27.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
$32.58M12.32N/AN/A$3.24 per share2.58
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$138.10M1.52$0.38 per share6.88($0.01) per share-260.00
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
$525.58M1.59N/AN/A$0.16 per share106.63
Evolus, Inc. stock logo
EOLS
Evolus
$266.27M2.36N/AN/A$0.09 per share108.11
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
$10.11M20.91N/AN/A$0.15 per share6.87
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
-$80.05M-$3.21N/AN/AN/AN/A-109.43%-76.65%N/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$31.87M$0.485.42N/AN/A28.22%-553.71%32.21%8/14/2025 (Estimated)
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
-$74.86MN/AN/AN/A-15.31%N/A-4.38%N/A
Evolus, Inc. stock logo
EOLS
Evolus
-$50.42M-$0.89N/AN/AN/A-20.40%-759.04%-20.14%7/30/2025 (Estimated)
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
-$75.40M-$0.36N/A14.71N/AN/A-218.44%-66.16%N/A

Latest EOLS, CTMX, CNCE, SPPI, and CXRXF Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
7/30/2025Q2 2025
Evolus, Inc. stock logo
EOLS
Evolus
-$0.09N/AN/AN/A$82.18 millionN/A
5/12/2025Q1 2025
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
$0.18$0.27+$0.09$0.27$35.42 million$50.92 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/AN/AN/AN/AN/A
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/AN/AN/AN/AN/A
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/AN/AN/AN/AN/A
Evolus, Inc. stock logo
EOLS
Evolus
N/AN/AN/AN/AN/A
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
N/A
9.03
9.03
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
N/A
1.73
1.73
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
257.04
2.39
1.61
Evolus, Inc. stock logo
EOLS
Evolus
22.00
2.34
2.16
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
N/A
2.71
2.38

Institutional Ownership

CompanyInstitutional Ownership
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
70.63%
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
67.77%
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
N/A
Evolus, Inc. stock logo
EOLS
Evolus
90.69%
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
21.67%
CompanyEmployeesShares OutstandingFree FloatOptionable
Concert Pharmaceuticals, Inc. stock logo
CNCE
Concert Pharmaceuticals
6447.94 million42.51 millionOptionable
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
17080.62 million75.30 millionOptionable
ADVANZ PHARMA Corp. Limited stock logo
CXRXF
ADVANZ PHARMA
42948.91 millionN/ANot Optionable
Evolus, Inc. stock logo
EOLS
Evolus
17064.48 million60.67 millionOptionable
Spectrum Pharmaceuticals, Inc. stock logo
SPPI
Spectrum Pharmaceuticals
86205.25 million199.70 millionOptionable

Recent News About These Companies

Spectrum Thin Films, Inc.
Company History - Paam Drugs and Pharmaceuticals

New MarketBeat Followers Over Time

Media Sentiment Over Time

Concert Pharmaceuticals stock logo

Concert Pharmaceuticals NASDAQ:CNCE

Concert Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which discovers and develops novel small molecule drugs through the use of deuterium technology. Its product candidates target a range of diseases including autoimmune disorders, inflammation, and central nervous system disorders. The company was founded by Richard H. Aldrich, Roger D. Tung and Christoph H. Westphal on April 12, 2006 and is headquartered in Lexington, MA.

CytomX Therapeutics stock logo

CytomX Therapeutics NASDAQ:CTMX

$2.60 +0.11 (+4.42%)
Closing price 04:00 PM Eastern
Extended Trading
$2.57 -0.03 (-1.15%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

ADVANZ PHARMA stock logo

ADVANZ PHARMA OTCMKTS:CXRXF

$17.06 0.00 (0.00%)
As of 06/10/2021

ADVANZ PHARMA Corp. Limited, a pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products worldwide. The company operates through two segments: ADVANZ PHARMA International and ADVANZ PHARMA North America. Its ADVANZ PHARMA International segment offers a portfolio of branded and generic prescription products to wholesalers, distributors, hospitals, and pharmacies. This segment's products include Brinavess for the conversion of onset atrial fibrillation to sinus rhythm in adults; Aggrastat, a reversible GP IIb/IIIa inhibitor indicated for use in patients with acute coronary syndrome; Xydalba, a semi-synthetic lipoglycopeptide for the treatment of acute bacterial skin and skin structure infections in adults; and Zevtera/Mabelio, a cephalosporin antibiotic for the treatment of community-acquired and hospital-acquired pneumonia. The company's ADVANZ PHARMA North America segment provides Donnatal for the treatment of irritable bowel syndrome; Zonegran for the treatment of partial seizures in adults with epilepsy; Nilandron for the treatment of metastatic prostate cancer; Lanoxin for the treatment of mild to moderate heart failure and atrial fibrillation; Plaquenil for the treatment of lupus and rheumatoid arthritis; and Photofrin for the treatment of certain types of cancer. It also offers Prostaglandin E1 formulations for the treatment of erectile dysfunction and peripheral arterial occlusive disease under the Prostavasin, Viridal, Vasaprostan, and Edex brands, as well as holds licensed commercialization rights to a pre-registration drug/device combination product, Trevyent for the treatment of pulmonary arterial hypertension. It sells its products through direct sales and local distribution relationships. The company was formerly known as ADVANZ PHARMA Corp. and changed its name to ADVANZ PHARMA Corp. Limited in December 2019. ADVANZ PHARMA Corp. Limited is headquartered in London, the United Kingdom.

Evolus stock logo

Evolus NASDAQ:EOLS

$9.73 +0.07 (+0.72%)
Closing price 04:00 PM Eastern
Extended Trading
$9.80 +0.07 (+0.77%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.

Spectrum Pharmaceuticals stock logo

Spectrum Pharmaceuticals NASDAQ:SPPI

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products. It offers ROLVEDON(Eflapegrastim), a novel long-acting granulocyte colony-stimulating factor for chemotherapy-induced neutropenia. The company develops Poziotinib, a novel irreversible tyrosine kinase inhibitor for non-small cell lung cancer tumors with various mutations. It has co-development, commercialization, and in-license agreements with Hanmi Pharmaceutical Co. Ltd.; a patent and technology license agreement with The University of Texas M.D. Anderson Cancer Center; and license agreement with Therapyx, Inc. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Boston, Massachusetts.